Venoms could be used to treat cancer and autoimmune diseases
Posted: 31 August 2018 | Iqra Farooq (Drug Target Review) | No comments yet
Venoms are continually being researched as potential chemicals for medicinal therapeutics to treat autoimmune diseases and diabetes…


A new class of drugs to treat autoimmune diseases, diabetes, chronic pain and many other conditions could be made using venom.
Venoms have been researched as potential medicinal agents for many years, with some snake, bee, and scorpion venoms having shown anti-tumour properties in previous studies in cell culture. Bee venom has also been used in many tribal areas in East Asia, with scorpion venom being used in traditional Chinese medicine.
Associate Professor Mandë Holford from The City University of New York and Hunter College explained how venom’s make up 15 percent of the Earth’s documents biodiversity, and that they can be found virtually all habitats.
Biomarkers aren’t just supporting drug discovery – they’re driving it
FREE market report
From smarter trials to faster insights, this report unpacks the science, strategy and real-world impact behind the next generation of precision therapies.
What you’ll unlock:
- How biomarkers are guiding dose selection and early efficacy decisions in complex trials
- Why multi-omics, liquid biopsy and digital tools are redefining the discovery process
- What makes lab data regulatory-ready and why alignment matters from day one
Explore how biomarkers are shaping early drug development
Access the full report – it’s free!
Very few venoms have actually been studied because researchers lacked appropriate methods of analysing the small amount of venom that could be extracted from the animals.
Innovation in omics analysis (technologies mapping the roles, relationships and actions od an organism’s molecular structure) allowed researchers to identify evolutionary changes and diversification among venomous species.
The researchers mentioned that this could prove useful in the development of new drugs capable of targeting and binding precisely to molecules that are active in human diseases.
The Food and Drug Administration (FDA) has only currently approved six venom-derived drugs from modern research, however the researchers in this study believe that greater investment could yield therapies from venom for currently untreatable diseases.
The scientists explain how therapeutic peptides derived from the venomous sea anemone could treat autoimmune diseases, therapeutic neurotoxins from the Conus magus could provide non-addictive treatment for chronic pain, chlorotoxin from the deathstalker scorpion could be the basis for a surgical tumour imaging technique, and spider toxins which could yield eco-friendly insecticides.
Prof Holford and her team concluded that an evolution informed perspective would help to focus the research, so the venoms can be used to transform therapeutics and bio-insecticides.
The study was published in the journal Science.
Related topics
Analysis, Disease Research, Drug Discovery, Peptide Therapeutics, Research & Development, Small molecule, Therapeutics
Related conditions
autoimmune diseases, Cancer, Diabetes
Related organisations
The City University of New York
Related people
Associate Professor Mandë Holford